Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-03-24

Clinical Trial Update: A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of dalcetrapib in patients with coronary artery disease was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dalcetrapib (dalcetrapib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Cardiovascular Disease | Phase 3 | Status: TERMINATED | Results posted: 2020-03-24